Riskpilot← Back to searchSign inGet full accessAthera Biotechnologies AB
ABIn liquidationOrg 5566206859Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20021 employees
Revenue 2020
SEK 0
EBITDA margin
—
+3% vs 2019
Equity ratio
85.6%
Financial strength
Net profit 2020
SEK -27,5M
+3% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK -27,6M | +3% |
| Net profit | SEK -27,5M | +3% |
| Total assets | SEK 15,1M | -58% |
| Equity | SEK 12,9M | -58% |
| Employees | 1 | — |
Legal name
Athera Biotechnologies AB
Org number
5566206859
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
18 februari 2002
Share capital
SEK 8 270 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolagets verksamhet skall bestå av att utveckla nya läkemedel och diagnostiska produkter samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 114 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −15 153 | −41 065 | −21 765 | −28 404 | −27 555 |
| Depreciation & amort. | −1 629 | −0 | −0 | −0 | −0 |
| EBIT | −16 782 | −41 065 | −21 765 | −28 404 | −27 555 |
| Net financials | 1 | 40 | 50 | 61 | 54 |
| Profit before tax | −16 781 | −41 025 | −21 715 | −28 343 | −27 501 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −16 781 | −41 025 | −21 715 | −28 343 | −27 501 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 15 625 | 31 693 | 9 495 | 36 110 | 15 109 |
| Equity | 9 850 | 26 100 | 4 385 | 30 435 | 12 934 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 776 | 5 593 | 5 111 | 5 675 | 2 175 |
| Total debt | 5 776 | 5 593 | 5 111 | 5 675 | 2 175 |
EBITDA margin
-2755500000.0%
This company
15.8%
Market median
-17439873518% vs market
20162020
Equity ratio
85.6%
This company
38.2%
Market median
+124% vs market
20162020
Return on equity
-212.6%
This company
18.4%
Market median
-1255% vs market
20162020
Net profit margin
-2750100000.0%
This company
8.1%
Market median
-33951851952% vs market
20162020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162020
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JO Liquidator | Liquidator | 2021 |
LB Chief Auditor | Chief Auditor | 2021 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Athera Biotechnologies AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Olov Ludvig Kling | Liquidator | 0 companies |
| Lena Birgitta Krause | Chief Auditor | 0 companies |
| Svein Arild Mathisen | Board of Directors | 0 companies |
| Carl Johan Kördel | Board of Directors | 0 companies |
| Gunnar Olof Olsson | Chairman | 0 companies |
| Sten Gunnar Otto Skolling | Board of Directors | 0 companies |